Saturday, May 21, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home News

New approach using RNA therapeutic can fix protein problems in cystic fibrosis

by Medical Finance
in News
New approach using RNA therapeutic can fix protein problems in cystic fibrosis
9
SHARES
102
VIEWS
Share on FacebookShare on Twitter

The process of generating proteins from genes is akin to a factory, where workers follow a set of instructions that, ideally, are effective and clear. But for some people who suffer from cystic fibrosis (CF), one of their genes has a mutation that results in confusing instructions for making the protein CFTR. The mutation inserts a stop sign in the wrong place, leading cells to make little to none of the protein. Without functional CFTR, patients have thick mucus in their lungs and difficulty getting nutrition from food.

Cold Spring Harbor Laboratory Professor Adrian Krainer and his former graduate student Young Jin Kim, an M.D.-Ph.D. student at Stony Brook University, have discovered a way to modify the message containing the instruction for CFTR, forcing the protein-making machinery to skip over this “stop sign” mutation, which allows a functional version of the protein to be made. They hope their new approach, using a specially designed RNA therapeutic, can contribute to the development of new treatments for CF patients with this mutation.

There is a significant unmet therapeutic need for patients with this type of mutation. Many mutations in the CFTR gene are not responsive to drugs used to treat CF.”


Young Jin Kim, an M.D.-Ph.D. student at Stony Brook University

Other efforts haven’t been especially effective. Encouraging all genes to plow through stop signs or cutting back on processes that break up messages from genes with unwanted stop signs have unintended side effects.

Krainer and Kim’s genetic manipulation deploys two antisense oligonucleotides (ASOs), one on either side of the segment that contains the stop sign mutation. In cultured human bronchial cells that express the stop sign mutation, Krainer and Kim set a detour, directing the cell to skip the wrong instruction and complete the rest of the protein. The technique does not need to work all the time in every cell, nor does the CFTR need to be a perfect protein. Krainer explains:

“We can show that this version of the protein has some activity. In cystic fibrosis, there’s been a lot of work, and so there were many reasons to believe that you don’t need to go to a hundred percent of the normal protein level, that somewhere between 10% and 30% would be substantially beneficial.”

The researchers plan to refine the ASO technique for CF systems beyond the Petri dish. They hope to progress toward clinical studies, following a path similar to the one that led to the first FDA-approved treatment for the genetic disorder SMA (spinal muscular atrophy).

Source:

Cold Spring Harbor Laboratory

Journal reference:

Kim, Y.J., et al. (2022) Exon-skipping antisense oligonucleotides for cystic fibrosis therapy. PNAS. doi.org/10.1073/pnas.2114858118.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study discovers how long-term memory T cells are formed after SARS-CoV-2 exposure

Study discovers how long-term memory T cells are formed after SARS-CoV-2 exposure

by Medical Finance
May 21, 2022
0

Exposure to SARS-CoV-2 by infection or vaccination generates immune cells that provide long-term immunity. These long-lived memory T cells play...

Scientists unravel how blood cells mount the first line of defense against viruses

Researchers elucidate first 3D structure of regulator protein complex

by Medical Finance
May 21, 2022
0

Proteins are indispensable components in living organisms. They are not only "building material" for the body – they also make...

‘Genetic scissors’ can give rise to unforeseen heritable mutations

‘Genetic scissors’ can give rise to unforeseen heritable mutations

by Medical Finance
May 21, 2022
0

CRISPR-Cas9, the "genetic scissors", creates new potential for curing diseases; but treatments must be reliable. In a new study, researchers...

NYBC discovers novel small-molecule pancoronavirus fusion inhibitors

Scientists reveal how 911 DNA checkpoint clamp helps repair the damaged DNA

by Medical Finance
May 21, 2022
0

When something goes wrong during DNA replication, cells call their own version of 911 to pause the process and fix...

Scientists identify genome regions linked to migraine risk

Scientists identify genome regions linked to migraine risk

by Medical Finance
May 21, 2022
0

An international consortium of leading migraine scientists identified more than 120 regions of the genome that are connected to risk...

Study: Safety, tolerability, and viral kinetics during SARS-CoV-2 human challenge. Image Credit: Jirsack / Shutterstock.com

SARS-CoV-2 human challenge study offers novel insights into viral kinetics

by Medical Finance
May 21, 2022
0

In a recent Nature Portfolio preprint*, researchers discuss the results of a human challenge study to provide novel insights into the...

Next Post
‘Lefty’ protein pumps the brakes during initial stages of embryo differentiation

Using 'off-the-shelf' engineered stem cell based therapy for treating glioblastomas post-surgery

VANTAstar

Micro Products with Macro Impact; The Role of Microplate Readers in Life Sciences

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Unique molecular signatures sustained in circulating monocytes and regulatory T cells in Convalescent COVID-19 patients. Image Credit: MohamadOuaidat/Shutterstock
    Study determines the molecular signatures of monocytes and regulatory T cells in the circulating blood of COVID-19 patients
  • Study: Inhibition of Protein N-Glycosylation Blocks SARS-CoV-2 Infection. Image Credit: Kateryna Kon / Shutterstock.com
    N-glycosylation blockers reduce SARS-CoV-2 infection
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply